Last reviewed · How we verify
Phenurone (PHENACEMIDE)
Phenurone (PHENACEMIDE) is a small molecule drug developed by Abbvie, targeting the sodium channel protein type 1 subunit alpha. It is classified as a phenacemide and was FDA-approved in 1951 for the treatment of epilepsy, specifically intractable complex partial seizures. As an off-patent medication, it is no longer protected by active patents, and there are currently no generic manufacturers. Phenurone works by modulating the activity of sodium channels in the brain, which helps to reduce the frequency and severity of seizures. Despite its long history, key safety considerations and pharmacokinetic parameters, such as half-life and bioavailability, remain unknown.
At a glance
| Generic name | PHENACEMIDE |
|---|---|
| Sponsor | Abbvie |
| Target | Sodium channel protein type 1 subunit alpha |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1951 |
Approved indications
- Epilepsy
- Epilepsy characterized by intractable complex partial seizures
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phenurone CI brief — competitive landscape report
- Phenurone updates RSS · CI watch RSS